This enzyme immunoassay (EIA) was developed to measure pyridoxal 5'-phosphate bound to albumin (PLP-HSA) in human serum. The monoclonal antibody titer was 1:2000 and a sequential saturation analysis curve, prepared with samples containing from 10 to 1000 nmol/L, showed a 50% Inhibition of antibody at 50 nmol of the conjugate per liter. The lower limit of detection for PLP-HSA was 10 nmoI/L, a sensitivity 1000-fold greater than that for any potential interferent. When serum samples gave negative results in the assay, we compared the antigenicity of the principal sites for PLP binding on HSA. It was apparent that the preferred physiological site was not antigenic; however, three additional sites for PLP binding on HSA elicited comparable antibody avidity. This EIA is potentially quite sensitive and specific for PLP-HSA, but considerable additional effort is required to convert serum PLP to an HSA-bound form detectable in the assay, which limitsits applicationas a screening method. Two areas to be addressed in assessing vitamin B6 nutriture are the need for reliable information on the overall status of B6 nutriture in the general population and a betterunderstanding of the interrelationships among the various B6 analogs in health and disease.Efforts to obtain
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This enzyme immunoassay (EIA) was developed to measure pyridoxal 5'-phosphate bound to albumin (PLP-HSA) in human serum. The monoclonal antibody titer was 1:2000 and a sequential saturation analysis curve, prepared with samples containing from 10 to 1000 nmol/L, showed a 50% Inhibition of antibody at 50 nmol of the conjugate per liter. The lower limit of detection for PLP-HSA was 10 nmoI/L, a sensitivity 1000-fold greater than that for any potential interferent. When serum samples gave negative results in the assay, we compared the antigenicity of the principal sites for PLP binding on HSA. It was apparent that the preferred physiological site was not antigenic; however, three additional sites for PLP binding on HSA elicited comparable antibody avidity. This EIA is potentially quite sensitive and specific for PLP-HSA, but considerable additional effort is required to convert serum PLP to an HSA-bound form detectable in the assay, which limitsits applicationas a screening method. this information have been complicated by uncertainties concerning which vitamin analog to monitor and by the general absence of a sensitive, accurate method with sufficient throughput for large population studies or that can accurately quantify all six forms of vitamin B6 in tissue and physiological fluids.
Vitamin B6 functions as a coenzyme in more than 100 different enzyme systems affectingthe metabolism of proteins, carbohydrates, and lipids. Pyridoxal 5'-phosphate, the active circulating form of the vitamin, is widely believed to be a sensitive and reliable indicator of vitamin B6 status (1) (2) (3) (4) (5) .' In addition, concentrations of circulating P12 correlate well with the P12 content of skeletal muscle, the major repository of B6 compounds in the body (6) (7) (8) (9) .
Numerous microbiological, enzymatic, and chemical assays have been developed for determining vitamin B6 in human serum. Today, however, there is still no one "best" method for status assessment capable of being adapted to mass screening or routine clinical use. In addition, a wide inter-laboratory disparity persists for measurements of B6 compounds in serum or plasma (10,11). Developing a radioimmunoassay (RIA), an enzyme-linked immunosorbent assay (EUSA), or an enzyme immunoassay (EIA) to detect physiologically bound forms of the vitamers, simplifying or eliminating sample extraction, has been recommended as a potentially promising approach (12).
Our purpose here was to develop a practical, accurate, and high-throughput assay for measuring P12 in serum. The availability of monoclonal antibody technology should make possible a specific, sensitive immunoassay for measuring nanomole per liter concentrations of P12.
MaterIals and Methods

Antigen
We mixed 2 mL of a 15 g/L keyhole limpet hemocyanin (KLH; Calbiochem, San Diego, CA) preparation with an equal volume of a 0.06 mol/L P12 solution, both prepared in 5 mmol/L triethanolamine hydrochloride buffer (pH 7.5), and reacted these for 1 h to ensure complete formation of the Schifi's base. We then reduced the corugate with 10 mg of sodium borohydride, keeping the reaction mixture on ice for 30 mm, then dialyzed the product extensively against multiple changes of the triethanolarnine buffer (13, 14) .
Protein was measured with the Bio-Rad Protein Assay (Bio-Rad Labs, Richmond, CA), and the amount of albumin-bound P12 produced was estimated from the absorbance at 325 nm, based on a molar absorptivity of 8300 L mol' cm' (15) (16) (17) . The P12/protein ratio of this preparation averaged 10 mmol of P12 per 100 g of KLH.
The immunogen was prepared by covalently coupling the antigen to 1-sm (diameter) polyaminostyrene microbeads (Pandex, Mundelein, IL) by the method of Reimer et al. (18, 19) .
Antisera Production
Six Charles River BALB/c mice were injectedintraperitoneally with about 100 ig of the protein antigen coiijugated to the microbeads. Six weeks later, a similar 100-jig injection was administered. Blood was sampled from the retro-orbital plexus one to two weeks later and analyzed for antibody production. The two mice with the highest antibody titers were given intravenous injections of approximately 50 jig of PLP-KLH on three consecutive days. Spleen cells were harvested two days later. The monoclonal antibodies and subsequent ascites fluid were produced essentially as described by Zola and Brooks (20) . We screened the fusion well supernates for a strong reaction to the reduced conjugate of bovine serum albumin saturated with pyridoxal 5'-phosphate. At the same time, we screened for a negative response to bovine and human serum albumin. We then screened the subsequent clones for positive response to P12-HSA; a negative response to HSA; and potential cross-reactivity with the various vitamin B6 analogs, both alone and conjugated to albumin. The isotype of the monoclonal antibodies was determined by using the Hybridoma Subisotyping Kit (Calbiochem).
Enzyme Immunoassay
We coated each well of 96-well microtiter plates (Immulon 2; Dynatech, Alexandria, VA) with 150 pL of rabbit antibody to human serum albumin (Calbiochem) diluted 10 000-fold in 0.01 mol/L carbonate buffer (pH 9.6-9.8) and left the plates at 25 #{176}C overnight. After decanting, we rinsed the plates five times with a Tris HC1 wash buffer (pH 8.0, 10 mmol/L) containing 0.5 mL ofTween 20 surfactant and 0.1 mL of thimerosal preservative per liter. We then added 150 jzL of blocking buffer to the plates; incubated at 37 #{176}C for 1 h, drained, and air-dried them. The blocking buffer, which is also the diluent for the monoclonal and second antibodies, is 10 mmolJL phosphatebuffered (pH 7.3-7.4) isotonic saline containing, per liter, 0.5 mL of Tween 20, 0.1 mL of thimerosal, and 10 mL of normal goat serum.
The plates can be covered and stored at 4 #{176}C at this stage or after the antigen has been added. Such stored plates maintain their integrity for at least six months.
After adding the antigen (150 pL of a 1,0 ng/jiL concentration of P12-HSA in blocking buffer), we incubated the plates for 1-2 hat 37#{176}C. The solutions were then decanted, and the plates were washed five times. We then added 150 p.L of the monoclonal antibody dilutions or of the monoclonal antibody from the saturation analysis (doscribed below) and let these react for 3 hat 37#{176}C. Unbound antibody was discarded, and the plates were washed an additional five times. The second antibody, goat anti-mouse IgG conjugated to horseradish peroxidase (EC 1.11.1.7; Calbiochem), was added (150 p1 of antibody-enzyme conjugate diluted 3000-fold in blocking buffer), and the plates were incubated for 1 h at 37 #{176}C. After decanting the excess second antibody and washing the plate five times, we added 150 ,uL of the enzyme substrate reagent and incubated for an additional hour at 37 #{176}C. The substrate reagent con- triethanolamine hydrochloride (pH 7.5), gently stir for 1 h at room temperature, then add urea to give a final concentration of8.0 molIL and stir for an additional hour. Cool the conjugate on ice, with stirring, while adding about 10 mg of sodium borohydride (the actual amount of reducing agent required depends on the concentration of P12-liSA; it should be added slowly until the yellow color disappears). After an additional hour of stirring to ensure complete reduction, dialyze the sample overnight, then return it to its original volume by ultrafiltration with Centriflo 25000 MW Membrane Cones (Amicon Corp., Lexington, MA).
We determined the quantity of "bound" PLP by measuring the inorganic phosphorus by inductively coupled plasma atomic emission spectroscopy (Thermo 1160 Atomcomp; Jarrell Ash, Waltham, MA). On the basis of the calculated concentration of P12, we made dilutions in blocking buffer for an eight-point standard curve with P12 concentrations ranging from 10 to 1000 nmoIJL.
Saturation Analysis
For the noncompetitive sequential saturation analysis we first incubated 100 JLL of the standards or test solutions with 200 p1 of the monoclonal antibody at 4#{176}C, overnight. The antibody was diluted 1500-fold, which resulted in a moderate excess of antibody relative to the highest standard concentration. A 150-jLL aliquot of this equilibrium reaction mixture was then added to the immobilized antigen on the microtiter plate. The unreacted antibody present binds the antigen on the plate at a concentration inversely proportional to the concentration of the standard or test antigen. We then continued the immunoassay as described previously.
Results
The IgGi monoclonal antibody selected was reactive with the reduced Schifi's base of P12-HSA, and it had a low affinity for, or was negative to, possible interfering substances. The nonphosphorylated analogs of pyridoxine were not reactive, as was free P12, the unreduced albumin conjugates, and reduced PLP-HSA at an added molar equivalence of <2 mol of P12 per mole of HSA. Detectable responses were elicited by a series of conjugates and PLY analogs (Table 1) , and the sensitivity of the assay for PLP-HSA was at least 1000-fold greater than that of any of the potential interfering compounds we tested.
Linear-regression analysis of the correlation between the concentration of pyridoxal 5'-phosphate conjugated to human serum albumin, as calculated from the absorbance of the pyridoxylamino groups at 325 nm (x), with PLP con- centration estimated from the analysis for inorganic phosphorus (y) resulted in a curve with a zero intercept, a slope of 1.425, standard error of0.05, and a correlation coefficient of 0.99. Subsequent dilutions used in preparing the standard curve were based on the PLY concentrations as determined by the analysis for phosphorus. (Table 2) suggest that PLP was bound at all proportions of PlY and HSA, but the PLP was not reactive with the antibody at <2 mol of PLY per mole of HSA. Similar results were observed by Dempsey and Christensen for bovine serum albumin (22). To better understand this result, we carried out a study in which Site I was blocked with 8.0 mol/L urea, after which 1, 2, and 10 mol of P12 were added per mole of HSA. After conjugation and quantification by phosphorus measurement, we diluted all samples, with and without urea, to the same concentrations and immunoassayed (Figure 2) .
The observed ratio of PLP/protein at the 1.0 molar equivalent was 0.91 without urea, 0.72 in the presence of urea. At a 2.0 molar equivalent, the respective results were 1.64 and 1.30, and at 10 equivalents, 4.22 and 2.37, respectively. All three preparations treated with urea produced essentially the same response curve. The samples without urea, however, when diluted to the same concentrations, gave curves indicating a much lower antigenic response.
Pyrldoxal-5-PhosDhate (nM) (24) . The antibody was selected on the basis of a positive response to the covalently bound and reduced pyridoxyl amino group, whereas the hybridomas were simultaneously screened for potential interferences from HSA and all other B6 analogs, both free and bound to human serum albumin, reduced and not reduced. Interference was not a problem: even pyridoxamine 5'-phosphate did not interfere at a concentration that would be a concern in clinical measurements. The selected antibody, in conjunction with a quantitative standard, produced an immunoassay capable of measuring the reduced Schifi's base of P12-HSA at 10 nmolfL with good specificity. Measurements of the phosphorus content to quantify the standard curve correlated well with absorbance measurements, but were more nearly accurate when there was chemical interference in the preparations.
While investigating the lack of antibody inhibition by the antigen when PLP was added to HSA at molar equivalents of<2.0, we observed that a 1.0 molar equivalent was not bound until 1.5 molar equivalent was added. Inhibition was detected only after a 1.0 molar equivalent was bound, so this probably reflected the Site I binding according to Dempsey and Christensen in their work on bovine serum albumin (22), which did not elicit an antigenic response. Our studies based on blocking this site with urea support this observation. In the standards prepared without urea, there was a nonantigenic presence of P12 bound to the albumin. When we prevented PLY from binding to Site I by including urea, PlY then bound to other areas on the albumin molecule and did elicit antibody binding. Results given in Figure 2 demonstrate that other sites of PLP binding to HSA, Dempsey's Site II and subsequent locations, are antigenic. P12 added in the presence of urea and reduced by sodium borohydride with resulting bound molar ratios of0.72, 1.30, and 2.37 mol ofPLP per mole of protein produced the same response curve when diluted to the same concentrations. These similar curves indicate a comparable, relative antibody avidity toward the additional sites. Thus the configuration of these sites must be very similar to Site H-that is, a reduced Schiffs base with the phosphate group available for antibody recognition.
When we analyzed serum samples by our immunoassay, the same phenomenon was observed. Without urea, a negative response was rendered, and when urea was added to the sample before reduction, we observed positive antibody inhibition. Therefore, we believe that the non-anti-10 OOC genic Site I is the preferred physiological binding site. We made numerous attempts to shift PLP quantitatively to a site that could be detected by the assay, such as isolating the albumin fraction before reduction, disassociating PLP by pH shift, then adding back to the urea treated albumin, or freeing endogenous PLP and conjugating to a second protein for Schifi's base reduction and immunoassay. These attempts had two serious drawbacks. Transferring PLP at nanomole per liter concentrations on a molecule that is present at 30 to 50 g/L made quantitative recovery quite difficult. In addition-and of major importance in this study-there was no sample preparation scheme available to present the physiological PLP in a form detectable by the immunoassay and still be feasible for the original intent of the method as a direct screening assay for PLP-HSA in serum.
In conclusion, our studies demonstrate different types of P12 binding sites on human albumin, with normal, physiological, circulating concentrations of PLP bound to Site I and not detected by our monoclonal antibody. It is apparent that our monoclonal antibody screening technique did not select an antibody to Site I or that this preferred binding site is in fact not antigemc. Therefore, the present method measures, with apparently adequate sensitivity and specificity, nanomole per liter concentrations of PLP-HSA. However, the considerable additional effort required to convert the physiological, circulating HSA-bound form of PLP to one detectable by the assay currently would limit our applying it as a screening method.
